Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial

Jay H. Fowke, Lauren Howard, Gerald L. Andriole, Stephen J. Freedland

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Objective Determine whether alcohol affects PCa risk among men taking the 5-ARI dutasteride. Design, settings, and participants Reduction by Dutasteride of Prostate Cancer Events was a 4-yr, multicenter, randomized, double-blind, placebo-controlled trial to compare PCa after dutasteride administration (0.5 mg/d) with placebo. Participants had a baseline prostate-specific antigen between 2.5 and 10.0 ng/ml and a recent negative prostate biopsy. Alcohol intake was determined by baseline questionnaire, and participants underwent a prostate biopsy to determine PCa status at 2 yr and 4 yr of follow-up.

Outcome measurements and statistical analysis Multivariable logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between alcohol intake and low-grade (Gleason <7) and high-grade (Gleason >7) PCa.

Results and limitations Of 6374 participants in our analysis, approximately 25% reported no alcohol consumption, 49% were moderate drinkers (one to seven drinks per week), and 26% were heavy drinkers (more than seven drinks per week). Alcohol intake was not associated with low- or high-grade PCa in the placebo arm and was not associated with low-grade PCa among men taking dutasteride. In contrast, men randomized to dutasteride and reporting more than seven drinks per week were 86% more likely to be diagnosed with high-grade PCa (p = 0.01). Among alcohol abstainers, dutasteride was associated with significantly reduced risk of high-grade PCa (OR: 0.59; 95% CI, 0.38-0.90), but dutasteride was no longer associated with reduced high-grade PCa among men reporting high alcohol intake (OR: 0.99; 95% CI, 0.67-1.45).

Conclusions Alcohol consumption negated a protective association between dutasteride and high-grade PCa.

Patient summary We confirmed a prior study that alcohol affects PCa prevention in patients taking 5-ARIs. Patients taking 5-ARIs may wish to eliminate alcohol intake if they are concerned about PCa.

Background Although most studies found no association between alcohol intake and prostate cancer (PCa) risk, an analysis of the Prostate Cancer Prevention Trial found that high alcohol intake significantly increased PCa risk among men randomized to the 5α-reductase inhibitor (5-ARI) finasteride.

Original languageEnglish
Pages (from-to)1133-1138
Number of pages6
JournalEuropean Urology
Volume66
Issue number6
DOIs
StatePublished - Dec 1 2014

Keywords

  • Alcohol trial
  • Dutasteride
  • Prostate cancer

Fingerprint Dive into the research topics of 'Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial'. Together they form a unique fingerprint.

  • Cite this